-
PloS One 2016The prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia (CBF-AML), including inv(16) and t(8;21) AML, is uncertain. We performed a... (Meta-Analysis)
Meta-Analysis Review
The prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia (CBF-AML), including inv(16) and t(8;21) AML, is uncertain. We performed a systematic review and meta-analysis of the effect of KIT mutations on the complete remission (CR) and relapse rates and overall survival (OS) of CBF-AML. PubMed, Embase, Web of Science, and the Cochrane Library were searched and relevant studies were included. Negative effect was indicated on relapse risk of CBF-AML (RR [relative risk], 1.43; 95%CI [confidence interval], 1.20-1.70) and t(8;21) AML (RR, 1.70; 95% CI, 1.31-2.21), not on OS of CBF-AML (RR, 1.09; 95% CI, 0.97-1.23), CR (OR [odds ratio], 0.95; 95% CI, 0.52-1.74), relapse risk (RR, 1.12; 95% CI, 0.90-1.41) or OS (RR, 1.03; 95% CI, 0.90-1.18) of inv(16) AML. Subgroup analysis of t(8,21) AML showed negative effect of KIT mutations on CR (OR, 2.03; 95%CI: 1.02-4.05), relapse risk (RR, 1.89; 95%CI: 1.51-2.37) and OS (RR, 2.26; 95%CI: 1.35-3,78) of non-Caucasians, not on CR (OR, 0.61; 95%CI: 0.19-1.95) or OS (RR, 1.12; 95%CI: 0.90-1.40) of Caucasians. This study indicates KIT mutations in CBF-AML to be included in the initial routine diagnostic workup and stratification system of t(8,21) AML. Prospective large-scale clinical trials are warranted to evaluate these findings.
Topics: Animals; Core Binding Factors; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis
PubMed: 26771376
DOI: 10.1371/journal.pone.0146614 -
Tumour Biology : the Journal of the... Jun 2017In the past decades, the oncogenic role of fibroblast growth factor receptor 2 has been demonstrated in a number of cancer types. However, studies have reported... (Meta-Analysis)
Meta-Analysis Review
In the past decades, the oncogenic role of fibroblast growth factor receptor 2 has been demonstrated in a number of cancer types. However, studies have reported contradictory findings concerning the correlation between fibroblast growth factor receptor 2 expression and prognosis in solid tumors. To address this discrepancy, we performed a meta-analysis with 18 published studies (2975 patients) retrieved from PubMed, EMBASE, and Web of science. Data were extracted and computed into odds ratios. The results showed that fibroblast growth factor receptor 2 overexpression was significantly associated with decreased 3-year overall survival (odds ratio = 1.93, 95% confidence interval: 1.30-2.85, p = 0.001) and 5-year overall survival (odds ratio = 1.62, 95% confidence interval: 1.07-2.44, p = 0.02) in patients with solid tumors. Subgroup analysis revealed that high fibroblast growth factor receptor 2 expression was also associated with poor prognosis of gastric cancer, hepatocellular carcinoma, and esophageal cancer, but not correlated with pancreatic cancer. In conclusion, fibroblast growth factor receptor 2 overexpression is correlated with decreased survival in most solid tumors, suggesting that the expression status of fibroblast growth factor receptor 2 is a valuable prognostic biomarker and a novel therapeutic target in human solid tumors.
Topics: Biomarkers, Tumor; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Prognosis; PubMed; Receptor, Fibroblast Growth Factor, Type 2
PubMed: 28618942
DOI: 10.1177/1010428317707424 -
Microvessel density as a prognostic factor in ovarian cancer: a systematic review and meta-analysis.Asian Pacific Journal of Cancer... 2015The prognostic value of microvessel density (MVD), reflecting angiogenesis, detected in ovarian cancer is currently controversial. Here we performed a meta-analysis of... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
The prognostic value of microvessel density (MVD), reflecting angiogenesis, detected in ovarian cancer is currently controversial. Here we performed a meta-analysis of all relevant eligible studies.
MATERIALS AND METHODS
A comprehensive search of online PubMed, Medline, EMBASE and Sciencedirect was performed to identify all related articles. The search strategy was designed as 'microvessel density', 'ovarian cancer', 'ovarian neoplasm', 'CD34' and 'angiogenesis'.
RESULTS
The studies were categorized by author/year, number of patients, FIGO stage, histology, cutoff value for microvessel density, types of survival analysis, methods of hazard rations (HR) estimation, HR and its 95% confidence interval (CI). Combined hazard ratios suggested that high MVD was associated with poor overall survival (OS) and progression-free survival (PFS), with HR and 95% CIs of 1.84 (1.33-2.35) and 1.36 (1.06-1.66), respectively. Subgroup analysis showed that high MVD detected by CD34 was relevant for OS [HR=1.67 (1.36-2.35)], but not MVD detected with other antibodies [HR=2.11 (0.90-3.31)]. Another subgroup analysis indicated that high MVD in patients without pre-chemotherapy, but not with pre- chemotherapy, was associated with OS [HR=1.88(1.59-2.18 and HR=1.70 (-0.18-3.59)].
CONCLUSIONS
The OS and PFS with high MVD were significant poorer than with low MVD in ovarian cancer patients. However, high MVD detected by CD34 seems to be more associated with survival for patients without pre-chemotherapy.
Topics: Female; Humans; Microvessels; Neovascularization, Pathologic; Ovarian Neoplasms; Prognosis
PubMed: 25735375
DOI: 10.7314/apjcp.2015.16.3.869 -
PloS One 2021GPRC5A is associated with various cancer initiation and progression. Controversial findings have been reported about GPRC5A prognostic characteristics, and no... (Meta-Analysis)
Meta-Analysis
BACKGROUND
GPRC5A is associated with various cancer initiation and progression. Controversial findings have been reported about GPRC5A prognostic characteristics, and no meta-analysis has been conducted to assess the relationship between GPRC5A and cancer prognosis. Therefore, the objective of this meta-analysis is to evaluate the overall prognostic effectiveness of GPRC5A.
METHODS
We first conducted a systematic search in the PubMed, Embase, Web of Science, CNKI, Cochrane, and WangFang databases. The hazard ratio (HR) and odds ratios (OR) with 95% CI were then pooled to assess the associations between GPRC5A expression and overall survival (OS), disease-free survival (DFS), event-free survival (EFS), and clinicopathological characteristics. Chi-squared test and I2 statistics were completed to evaluate the heterogeneity in our study. A random-effects model was used when significant heterogeneity existed (I2>50% and p<0.05); otherwise, we chose the fixed-effect model. Subgroup analysis was stratified by tumor type, region, HR obtained measurements, and sample capacity to explore the source of heterogeneity.
RESULTS
In total, 15 studies with 624 patients met inclusion criteria of this study. Our results showed that higher expression of GPRC5A is associated with worse OS (HR:1.69 95%CI: 1.20-2.38 I2 = 75.6% p = 0.000), as well as worse EFS (HR:1.45 95%CI: 1.02-1.95 I2 = 0.0% p = 0.354). Subgroup analysis indicated that tumor type might be the source of high heterogeneity. Additionally, cancer patients with enhanced GPRC5A expression were more likely to lymph node metastasis (OR:1.95, 95%CI 1.33-2.86, I2 = 43.9%, p = 0.129) and advanced tumor stage (OR: 1.83, 95%CI 1.15-2.92, I2 = 61.3%, p = 0.035), but not associated with age, sex, differentiation, and distant metastasis.
CONCLUSION
GPRC5A can be a promising candidate for predicting medical outcomes and used for accurate diagnosis, prognosis prediction for patients with cancer; however, the predictive value of GPRC5A varies significantly according to cancer type. Further studies for this mechanism will be necessary to reveal novel insights into application of GPRC5A in cancers.
Topics: Disease-Free Survival; Humans; Neoplasms; Prognosis; Progression-Free Survival; Publication Bias; Receptors, G-Protein-Coupled
PubMed: 33788883
DOI: 10.1371/journal.pone.0249040 -
BMJ Open Sep 2021To assess the role of sex as an independent prognostic factor for mortality in patients with sepsis admitted to intensive care units (ICUs). (Meta-Analysis)
Meta-Analysis
OBJECTIVE
To assess the role of sex as an independent prognostic factor for mortality in patients with sepsis admitted to intensive care units (ICUs).
DESIGN
Systematic review and meta-analysis.
DATA SOURCES
MEDLINE, Embase, Web of Science, ClinicalTrials.gov and the WHO Clinical Trials Registry from inception to 17 July 2020.
STUDY SELECTION
Studies evaluating independent associations between sex and mortality in critically ill adults with sepsis controlling for at least one of five core covariate domains prespecified following a literature search and consensus among experts.
DATA EXTRACTION AND SYNTHESIS
Two authors independently extracted and assessed the risk of bias using Quality In Prognosis Studies tool. Meta-analysis was performed by pooling adjusted estimates. The Grades of Recommendations, Assessment, Development and Evaluation approach was used to rate the certainty of evidence.
RESULTS
From 14 304 records, 13 studies (80 520 participants) were included. Meta-analysis did not find sex-based differences in all-cause hospital mortality (OR 1.02, 95% CI 0.79 to 1.32; very low-certainty evidence) and all-cause ICU mortality (OR 1.19, 95% CI 0.79 to 1.78; very low-certainty evidence). However, females presented higher 28-day all-cause mortality (OR 1.18, 95% CI 1.05 to 1.32; very low-certainty evidence) and lower 1-year all-cause mortality (OR 0.83, 95% CI 0.68 to 0.98; low-certainty evidence). There was a moderate risk of bias in the domain adjustment for other prognostic factors in six studies, and the certainty of evidence was further affected by inconsistency and imprecision.
CONCLUSION
The prognostic independent effect of sex on all-cause hospital mortality, 28-day all-cause mortality and all-cause ICU mortality for critically ill adults with sepsis was uncertain. Female sex may be associated with decreased 1-year all-cause mortality.
PROSPERO REGISTRATION NUMBER
CRD42019145054.
Topics: Adult; Critical Illness; Female; Hospital Mortality; Humans; Intensive Care Units; Prognosis; Sepsis
PubMed: 34551945
DOI: 10.1136/bmjopen-2021-048982 -
International Journal of Surgery... Jul 2019Many reports have shown that the prognostic nutritional index (PNI) is associated with the progression of malignant tumors. We comprehensively evaluated the prognostic... (Meta-Analysis)
Meta-Analysis
BACKGROUND AND AIMS
Many reports have shown that the prognostic nutritional index (PNI) is associated with the progression of malignant tumors. We comprehensively evaluated the prognostic significance of the PNI in patients with gynecological cancer.
METHODS
We identified relevant studies by searching PubMed, Embase, the Cochrane Library, and the Web of Science. The hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (CI) were used to explore the correlation between PNI and overall survival (OS), progression-free survival (PFS), and the characteristics of gynecological cancer. All analyses were performed using Review Manager ver. 5.2 software.
RESULTS
We included nine studies with 2373 patients. The PNI correlated closely with the OS and PFS of gynecological cancer; the pooled HRs were respectively 2.66 (95% CI 1.56-4.55) and 2.43 (95% CI 2.07-2.86) on univariate analysis (UVA) and 1.88 (95% CI 1.10-3.20) and 1.92 (95% CI 1.52-2.44) on multivariate analysis (MVA).
CONCLUSIONS
The PNI is significantly associated with the prognosis of patients with gynecological cancer, and may, in fact, be independently prognostic.
Topics: Disease Progression; Female; Genital Neoplasms, Female; Humans; Multivariate Analysis; Nutrition Assessment; Nutritional Status; Odds Ratio; Prognosis; Proportional Hazards Models
PubMed: 31185310
DOI: 10.1016/j.ijsu.2019.05.018 -
Medicina (Kaunas, Lithuania) Jan 2023: Postoperative pancreatic fistula (POPF) is one of the most challenging complications after pancreatic resections, associated with prolonged hospital stay and high... (Review)
Review
: Postoperative pancreatic fistula (POPF) is one of the most challenging complications after pancreatic resections, associated with prolonged hospital stay and high mortality. Early identification of pancreatic fistula is necessary for the treatment to be effective. Several prognostic factors have been identified, although it is unclear which one is the most crucial. Some studies show that post-pancreatectomy hypophosphatemia may be associated with the development of POPF. The aim of this systematic review was to determine whether postoperative hypophosphatemia can be used as a prognostic factor for postoperative pancreatic fistula. : The systematic literature review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations (PRISMA) and was registered in the International Prospective Register of Systematic Reviews (PROSPERO). The PubMed, ScienceDirect, and Web of Science databases were systematically searched up to the 31st of January 2022 for studies analyzing postoperative hypophosphatemia as a prognostic factor for POPF. Data including study characteristics, patient characteristics, operation type, definitions of postoperative hypophosphatemia and postoperative pancreatic fistula were extracted. : Initially, 149 articles were retrieved. After screening and final assessment, 3 retrospective studies with 2893 patients were included in this review. An association between postoperative hypophosphatemia and POPF was found in all included studies. Patients undergoing distal pancreatectomy were more likely to develop severe hypophosphatemia compared to patients undergoing proximal pancreatectomy. Serum phosphate levels on postoperative day 4 (POD 4) and postoperative day 5 (POD 5) remained significantly lower in patients who developed leak-related complications showing a slower recovery of hypophosphatemia from postoperative day 3 (POD 3) through postoperative day 7 (POD 7). Moreover, body mass index (BMI) higher than 30 kg/m, soft pancreatic tissue, abnormal white blood cell count on postoperative day 3 (POD 3), and shorter surgery time were associated with leak-related complications (LRC) and lower phosphate levels. : Early postoperative hypophosphatemia might be used as a prognostic biomarker for early identification of postoperative pancreatic fistula. However, more studies are needed to better identify significant cut-off levels of postoperative hypophosphatemia and development of hypophosphatemia in the postoperative period.
Topics: Humans; Pancreatic Fistula; Prognosis; Retrospective Studies; Hypophosphatemia; Postoperative Complications; Phosphates; Postoperative Period; Risk Factors
PubMed: 36837475
DOI: 10.3390/medicina59020274 -
TheScientificWorldJournal 2014Vascular endothelial growth factor (VEGF) and microvessel density (MVD) are associated with greater incidence of metastases and decreased survival. Whether they can be... (Meta-Analysis)
Meta-Analysis Review
BACKGROUND
Vascular endothelial growth factor (VEGF) and microvessel density (MVD) are associated with greater incidence of metastases and decreased survival. Whether they can be used as prognostic indicators of colorectal cancer (CRC) is still controversial.
METHODS
The authors performed a meta-analysis using the results of a literature search of databases of PubMed and EMBASE, and the references of articles included in the analysis. Meta-analysis was performed using random effects model and hazard ratios (HRs) and 95% confidence intervals (CIs) as effect measures.
RESULTS
Twenty studies contributed to the analysis of VEGF, of which 16 were used for overall survival (OS) and 9 for disease-free survival (DFS). High VEGF levels has a relationship with unfavorable survival (OS: HR = 1.98, 95% CI: 1.30-3.02; DFS: HR = 2.10, 95% CI: 1.26-3.49) and a 4.22-fold increase in the rate of distant metastases. Analysis was performed on 18 studies for MVD; the results showed that patients with high MVD expression in tumors appeared to have poorer overall survival (HR = 1.39, 95% CI: 1.22-1.58) and were at a greater risk of having unfavorable clinical characteristics related to prognosis. Corresponding results were obtained from quantitative and/or qualitative analysis of clinicopathological.
CONCLUSIONS
The meta-analysis demonstrates that VEGF and MVD can be used as prognostic biomarkers for CRC patients.
Topics: Biomarkers; Colorectal Neoplasms; Humans; Microvessels; Prognosis; Vascular Endothelial Growth Factor A
PubMed: 25143961
DOI: 10.1155/2014/102736 -
Journal of B.U.ON. : Official Journal... 2015Kallikrein is considered as a mediator of tumorigenesis. Various studies examing the relationship between high kallikrein expressions with the clinical outcome in... (Meta-Analysis)
Meta-Analysis Review
PURPOSE
Kallikrein is considered as a mediator of tumorigenesis. Various studies examing the relationship between high kallikrein expressions with the clinical outcome in patients with ovarian cancer have yielded controversial conclusions.
METHODS
We conducted a meta-analysis of 10 studies (N=1478) that evaluated the relationship between positive kallikrein expression and overall survival and progression-free survival (PFS). Data were analyzed with random effect and combined hazard ratios (HR) by STATA software.
RESULTS
Positive kallikrein expression was significantly associated with worse OS (HR for OS was 2.01, 95%CI: 1.68-2.34, p<0.05). Subgroup analysis showed that kallikrein detected by RT-PCR was related with OS (HR=2.51, 95%CI: 2.16-2.86, p<0.05), as well as by nonY-PCR methods (HR=1.6, 95%CI: 1.08-2.12, p<0.05). The heterogeneity among studies was significant (I2-91%, p=0.000). Begg's and Egger's test showed p=0.813 and p=0.938, respectively. The estimated HR for PFS was 1.83, 95%CI: 1.51-2.14, p<0.05). The heterogeneity among studies was significant (I2=88.9%, p=0.000). Begg's and Egger's test showed p=0.93 and p=0.88, respectively. Furthermore, confunnel plot (contour-enhanced funnel plot) was undertaken which also showed absence of publication bias for both OS and PFS.
CONCLUSION
Although the presence of some modest bias cannot be avoided, positive kallikrein expression seems to be associated with worse OS and PFS in patients with ovarian cancer.
Topics: Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Kallikreins; Neoplasm Staging; Ovarian Neoplasms; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Up-Regulation
PubMed: 26214640
DOI: No ID Found -
PeerJ 2023The receptor for activated C kinase 1 (RACK1) expression is associated with clinicopathological characteristics and the prognosis of various cancers; however, the... (Meta-Analysis)
Meta-Analysis
BACKGROUND
The receptor for activated C kinase 1 (RACK1) expression is associated with clinicopathological characteristics and the prognosis of various cancers; however, the conclusions are controversial. As a result, this study aimed to explore the clinicopathological and prognostic values of RACK1 expression in patients with cancer.
METHODOLOGY
PubMed, Embase, Web of Science, Cochrane Library, and Scopus were comprehensively explored from their inception to April 20, 2023, for selecting studies on the clinicopathological and prognostic role of RACK1 in patients with cancer that met the criteria for inclusion in this review. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the prognosis-predictive value of RACK1 expression, while pooled odds ratios (ORs) and 95% CIs were used to evaluate the correlation between RACK1 expression and the clinicopathological characteristics of patients with cancer. The quality of the included studies was evaluated using the Newcastle-Ottawa Scale.
RESULTS
Twenty-two studies (13 on prognosis and 20 on clinicopathological characteristics) were included in this systematic review and meta-analysis. The findings indicated that high RACK1 expression was significantly associated with poor overall survival (HR = 1.62; 95% CI, 1.13-2.33; = 0.009; I = 89%) and reversely correlated with disease-free survival/recurrence-free survival (HR = 1.87; 95% CI, 1.22-2.88; = 0.004; I = 0%). Furthermore, increased RACK1 expression was significantly associated with lymphatic invasion/N+ stage (OR = 1.74; 95% CI, 1.04-2.90; = 0.04; I = 79%) of tumors.
CONCLUSIONS
RACK1 may be a global predictive marker of poor prognosis in patients with cancer and unfavorable clinicopathological characteristics. However, further clinical studies are required to validate these findings.
Topics: Humans; Disease-Free Survival; Neoplasm Proteins; Neoplasms; Prognosis; Receptors for Activated C Kinase
PubMed: 37601269
DOI: 10.7717/peerj.15873